This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
800
Safety as measured by Physical examination, adverse events, vital signs, and laboratory tests.
Physical examination, adverse events, vital signs, and laboratory tests.
Time frame: 8 weeks
Change in the clinician reported photonumeric score
Time frame: 8 weeks post the start of treatment
Change in the patient reported global abdominal perception score
Time frame: 8 weeks post the start of treatment
Change in waist circumference
Time frame: 8 weeks post the start of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
WG Clinical Research
Tucson, Arizona, United States
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Clinical Testing Center of Beverly Hills
Beverly Hills, California, United States
Center for Dermatology Cosmetic and Laser Surgery
Fremont, California, United States
Dermatology/Cosmetic Laser Associates of La Jolla, Inc
San Diego, California, United States
University Clinical Trials, Inc.
San Diego, California, United States
Clinical Science Institute
Santa Monica, California, United States
The Center for Clinical & Cosmetic Research
Aventura, Florida, United States
Skin Care Research, Inc.
Boca Raton, Florida, United States
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States
...and 21 more locations